key: cord-0287096-jtmlqk1l
authors: Gauthier, L. R.; Robichaud, L.-A.; Bouffard, M.; Therrien, F.; Beland, S.; Bouvrette, M.; Gewandter, J.; Gagliese, L.; Dworkin, R. H.; Lemieux, J.; Savard, J.; Jackson, P.; Aubin, M.; Lauzier, S.; Gagnon, B.; Dionne, A.; Shobbrook, C.; Gagnon, P.
title: Factors associated with chemotherapy-induced peripheral neuropathy-related reduced taxane dose or premature discontinuation in women with early-stage breast cancer
date: 2021-09-16
journal: nan
DOI: 10.1101/2021.09.13.21263539
sha: ce17cd25ed9d07e014631b09697598f79bad5f89
doc_id: 287096
cord_uid: jtmlqk1l

Purpose: In the absence of treatments for chemotherapy-induced peripheral neuropathy (CIPN), dose reductions (DR) and premature discontinuation (PD) are primary management strategies. However, decision-making guidance is insufficient and knowledge of factors associated with DRPD is limited. We examined biopsychosocial factors associated with CIPN-related DR/PD in women undergoing taxane-based chemotherapy for early-stage breast cancer. Patients and methods: As part of a longitudinal study of CIPN measurement, women completed assessments before the first taxane infusion and at the final infusion or within the originally expected timeframe for the final infusion. Participants completed self-report measures of CIPN, pain, and physical and psychosocial wellbeing, and underwent physical testing of lower limb disability and Quantitative Sensory Testing for sensation and pain threshold to thermal, vibration, and touch stimuli in the feet and hands. Sociodemographic and clinical data were collected. Logistic regression was used to identify factors associated with neuropathy-related DRPD. Results: Among 121 participants, 66 (54.5%) received taxane-as-prescribed, 46 (38.0%) had neuropathy-related DRPD, and 9 (7.4%) had DR/PD for other reasons. Factors associated with neuropathy-related DR/PD were receipt of paclitaxel (Odds Ratio [OR]=75.05, 95% Confidence Interval [CI] 2.56-2197.96]), lower pre-treatment pain catastrophizing (OR=0.72, 95% CI: 0.54-0.95), and higher post-treatment neuropathic pain (OR=10.77, 95% CI: 1.99-58.15) and sensitivity to cold pain in the hand (OR=1.64, 95% CI: 1.05-2.56). Conclusion: CIPN-related DRPD is associated with paclitaxel treatment and post-treatment neuropathic pain and cold pain sensitivity in the hands. CIPN communication to healthcare providers may be influenced by pain catastrophizing, suggesting symptom appraisal may be an important factor in communication. Findings could contribute to clinical practice recommendations to facilitate treatment decision-making.

5 providers may be influenced by pain catastrophizing, suggesting symptom appraisal may be an important factor in communication. Findings could contribute to clinical practice recommendations to facilitate treatment decision-making.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 INTRODUCTION Chemotherapy-induced peripheral neuropathy (CIPN) affects 43%-80% of women undergoing taxane-based treatment (paclitaxel, docetaxel) for breast cancer (BC) [1] [2] [3] . It involves sensory symptoms like pain, numbness, tingling, and/or cold allodynia, with motor weakness occurring at high doses 4,5 . Duloxetine is the only treatment recommended for painful CIPN 4,6 .

However, its efficacy for the myriad sensory, motor, and autonomic symptoms other than pain has not been established.

In the absence of available treatments, dose reductions or premature discontinuation (DR/PD) are primary management strategies 7 , which have been reported in 5% to 35% of women with early-stage BC 3,10-15 . The American Society of Clinical Oncology (ASCO) guidelines recommend discussion with patients about treatment changes, including DR/PD, "in the case of intolerable neuropathy and/or functional nerve impairment" 4 . However, they offer no guidance about the characteristics of intolerance or impairment warranting a DR/PD decision.

Similarly, clinical monograph treatment change recommendations are inconsistent and insufficient for decision-making 14 .

CIPN-related DR/PD risk factor knowledge is limited. While paclitaxel is associated with CIPN-related treatment alterations, tumor characteristics, age, alcohol use, and history of diabetes are not 12, 25 . Unfortunately, no studies have compared people with CIPN-related DR/PD to people who received treatment-as-prescribed on a broad range of biopsychosocial factors. This could provide important information about potentially modifiable factors.

Like other cancer pain 26, 27 , CIPN is associated with biopsychosocial factors. Since the guidelines recommend DR/PD discussion for intolerable CIPN 4 , an understanding of biopsychosocial factors associated with CIPN presence or severity may provide insight. CIPN . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 presence and severity are associated with paclitaxel treatment and dose 18 , greater post-treatment depression, anxiety, and insomnia, lower quality of life (QOL) 19-21 and physical wellbeing 3 , balance problems and falls 29, [32] [33] [34] , and impaired functioning 35, 36 . Greater pre-treatment anxiety, depression and fatigue also predict post-treatment CIPN presence and severity 37, 38 .

Since the guidelines also recommend DR/PD discussion for impaired nerve fiber functioning 4 , quantitative sensory testing (QST) may also provide insight. QST quantifies sensory nerve fiber functioning through tests of sensation and pain threshold to stimuli, like thermal, touch, and vibration. It can track sensory changes throughout treatment 17, 18, 39 , improve CIPN detection, and guide decision-making 7,40 . For example, cold allodynia and hyperalgesia in the hand predicts severe neuropathy 33 , people with CIPN have lower heat pain threshold than people without CIPN 34 , and moderate-to-severe CIPN is associated with reduced tactile and vibration perception in some studies 26 , but not others 35 . Studies of CIPN-related DR/PD using QST do not exist. Thus, the role of impaired nerve fiber functioning is unknown.

Insufficient decision-making guidance is problematic: By the time DR/PD must be considered, CIPN reversibility is unknown. Moreover, DR/PD may reduce treatment efficacy, with unclear impacts on long-term survival 14 . A better understanding of factors associated with CIPN-related DR/PD could improve decision-making guidance by clarifying the type of intolerance and functional nerve impairment associated with DR/PD and identifying people atrisk to intervene on modifiable factors. This study aims to evaluate biopsychosocial factors associated with CIPN-related DR/PD in women undergoing taxane-based chemotherapy for early-stage BC.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

As part of a longitudinal study on CIPN measurement, women with early-stage BC were recruited before starting taxane-based chemotherapy at the Centre des maladies du sein The project was presented during weekly chemotherapy patient education classes.

Interested attendees signed a pre-consent form granting permission to access their medical files to verify eligibility and be contacted via telephone. Study visits were scheduled before the first chemotherapy cycle or ≤2 weeks for regimens not starting with taxane (T0). Written informed consent was obtained before data collection. The second assessment (T1) took place at the final taxane infusion (±1 week) or within the originally expected timeframe for the final infusion 38 .

At each assessment, sociodemographic and clinical information were collected or updated and a short QST protocol 39 and a physical functioning assessment were conducted. Self-report measures were completed before the first infusion (T0) and ≤7 days after T1. Questionnaire, QST, and physical functioning test order was randomized. Clinical data were abstracted from the electronic medical record (EMR) at T0 and updated at T1.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Measures Sociodemographic data, and pain history, and management were collected via brief interview. Clinical data abstracted from the EMR and the CHU de Québec-Université Laval oncology registry included information about cancer and treatment factors, medical comorbidities, and prescribed medications. The Research Assistant (RA) completed the Charlson Comorbidity Index (CCI) 40 and calculated the Anticholinergic Drug Scale (ADS) 41 because of the relationship between anticholinergic load and pain 42 .

Following chart review, participants were categorized into 3 groups according to receipt of prescribed taxane and reasons for DR/PD. DR/PD was coded as neuropathy-related if consultation notes mentioned neuropathy, paresthesia, dysesthesia, pain in the periphery, and/or motor weakness as the reason for DR/PD. Each participant was coded by two independent raters. Disagreements were reviewed until consensus was reached. Group 1 (G1) received taxane-asprescribed, Group 2 (G2) had neuropathy-related DR/PD, and Group 3 (G3) had DR/PD for other reasons.

The Pain History Questionnaire (PHQ) 43 collected information about the presence of cancer-related and non-cancer pain on most days in the past 3 months. We also calculated average expected pain immediately and 1 week after chemotherapy, and after pain treatment on 0 (no pain) to 10 (worst possible pain) numeric rating scales. 45 . Spontaneous ongoing pain, paroxysmal and evoked pain, dysesthesia and paresthesia were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Using an adapted protocol 39 we assessed cold (CPT) and heat pain threshold (HPT), and cool (CDT), warm (WDT), vibration (VDT; TSAII NeuroSensory Analyzer & VSA 3000, Medoc, Israel), and mechanical detection threshold (MDT; SenseLab Aesthesiometer II handheld nylon filaments, Somedic, Sweden) on the dorsum of the right hand and foot 41,59 . A 3cm X 3cm thermode was used for thermal tests. Baseline temperature was 32°C with 0.5°C/sec rate of change and maximum cooling and warming at 0° C and 50.5°C. The thermode was immediately removed upon response. Baseline vibration was 0µm/sec with 1µm/sec rate of change. Thermal and vibration thresholds were calculated from the mean of three trials. MDT was calculated as the geometric mean (grams). Higher WTD, HPT, VDT, and TDT reflect less sensitivity. Higher CDT and CPT reflect greater sensitivity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint

The Karnofsky Performance Status Scale (KPS) 60,61 , a measure of observer-rated functioning, was completed by the RA. Use of a walking accessory and number of falls 24 or near-falls in the past week (T0) and since T0 (T1) were recorded by the RA. Balance and mobility was assessed with the Timed Up and Go Test (TUG) 62,63 which was calculated from the mean of 2 trials. The Short Physical Performance Battery Protocol (SPPB) 57 was performed to assess static balance.

Missing data were screened and the pattern analyzed using Little's Missing Completely at Random test 58 . Where self-report items were missing-at-random or completely-at-random, scores were calculated based on completed items. Scores were not imputed for measures missing data on all items. Statistical significance was set at p≤0.05. T-tests and χ 2 analyses assessed whether participants who completed both assessments differed from those who did not complete T1 on baseline data. Means, standard deviations (SD), frequencies, and percentages were used to characterize participants. Repeated measures t-tests, Cochrane Q, and Wilcoxon tests were used to evaluate change.

To determine candidate correlates for the multivariate regression model, bivariate analyses, including one-way ANOVAs and χ 2 analyses were used to compare groups on sociodemographic, clinical, and T0 and T1 QST, physical functioning, and self-report measures.

Post-hoc analyses determined pair-wise group differences. Correlates significantly different (p≤0.05) across groups were considered for model entry, a more conservative level than recommended 59 to control for overfitting. We included corresponding T0 variables for each T1 variable included to control for pre-treatment values, and vice versa. Correlates highly associated . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 with each other (r≥0.7) 59,60 were evaluated for missing data, assumption violations, or effect sizes to determine which variable to retain. We used standard binomial logistic regression as G3 was too small taking into account missing data (n=4). Analyses were conducted using SPSSv25. Figure 1 describes participant recruitment and retention. 154 (59,2%) women consented to participate. Five (3.2%) were subsequently excluded and 1 (0.6%) withdrew before T0. 148 and 121 (81.1% retention) participants completed T0 and T1, respectively. Compared to participants who completed T1, those who did not were older (p≤0.05), less educated (p≤0.001), less likely to exercise (p≤0.05), had higher BMI (p≤0.05) and KPS (p≤0.05), and were less sensitive to foot and hand MDT (p≤0.05). Data were missing at random 58 and were not associated with baseline self-report pain or symptoms.

Subsequent analyses include participants who completed both assessments (n=121).

Descriptive data and T0-T1 change are presented in Table 1 . Participants were 50.9±11.1 years old, mostly Caucasian, partnered, and well-educated. Few (2.5%) had ≥1 CCI comorbidity.

Paclitaxel was more frequently prescribed than docetaxel.

With the exception of SF-MPQ-2 Affective, scores on all measures of pain and CIPN were significantly worse at T1 than T0. No participants were prescribed duloxetine. Frequency of pharmacological and nonpharmacological pain treatment frequency did not increase over time.

With the exception of foot and hand CDT, QST parameters were significantly different at T1 compared to T0, demonstrating nerve fiber functioning changes following chemotherapy.

KPS was lower and TUG was higher at T1 than T0, suggesting worse observer-rated functioning and balance and mobility, respectively. Falls and SPPB did not change.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint While PSQI did not change, FACIT-Fatigue and FACT-Physical, Functional, and Social wellbeing were worse at T1 than T0.

Sixty-six (54.5%; G1) participants received taxane-as-prescribed. 46 ( 

Correlates retained for consideration for entry into the multivariable model were age, taxane molecule, T0 PCS and KPS, and T1 NPSI, Fact-Taxane, SF-MPQ-2 Neuropathic, foot and hand CPT, KPS and TUG (Table 2 ). T1 prescribed gabapentin/pregabalin, foot VDT, BPI Interference, and FACIT-Fatigue were not retained because group differences were only among G3 versus G1 or G2.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint T0 and T1 foot and hand CPT were highly correlated (r≥0.71, p<0.001). We retained both based on CIPN localization differences 61 . T1 NPSI and SF-MPQ-2 Neuropathic were also highly correlated (r=0.76, p<0.001). SF-MPQ-2 Neuropathic was retained over the NPSI due to larger G1 vs G2 effect size (Cohen's d= -1.2; and -0.7, respectively).

All variance inflation factors (VIF) were acceptable at ≤3.03 59 , suggesting moderate correlations. This is expected because of the repeated-measures nature of the data and does not require correction 62 . The model ( 

This is the first study to examine biopsychosocial factors associated with CIPN-related DR/PD in women undergoing taxane-based chemotherapy for early-stage BC. 38% of women had CIPN-related DR/PD, the most common reason for DR/PD. Although our approach to determining whether DR/PD was CIPN-related was not based on a standardized clinical diagnosis, it reflects how CIPN is commonly assessed in clinical practice, thereby maximizing generalizability of findings to the community. Despite worse post-treatment CIPN and pain, no one was prescribed duloxetine, the only recommended agent for painful CIPN 4 . Prescriptions for other analgesics (e.g. gabapentin/pregabalin) and use of other treatments did not increase following chemotherapy. Contrary to assumptions that DR/PD exclusively reflects CIPN . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint severity 10 , we found that the factors associated with DR/PD were biopsychosocial, including receipt of paclitaxel, greater post-treatment neuropathic pain and cold pain sensitivity in the hand, and lower pre-treatment pain catastrophizing. This study provides important information about the type of CIPN-related intolerance and functional nerve impairment associated with DR/PD decision-making to help refine guidelines.

Several findings are consistent with known risk factors for CIPN presence and severity.

Consistent with the known dose limiting effects of paclitaxel 10,12,25 and higher incidence of neurotoxicity with paclitaxel than docetaxel 64 , receipt of paclitaxel was associated with a greater likelihood of DR/PD than receipt of docetaxel.

The relationship of higher post-treatment neuropathic pain with CIPN-related DR/PD is not surprising given associations between self-report neuropathic pain and CIPN severity 36,71,72 .

However, it is interesting that a similar relationship was not detected with FACT-Taxane scores.

It is possible that patients report that symptoms are intolerable, or clinicians interpret them as such, when they reflect neuropathic pain, rather than non-painful neuropathy. It is also possible that the FACT-Taxane has insufficient sensitivity for CIPN-related DR/PD. Future research should compare the discriminant properties of CIPN and neuropathic pain measures across CIPN outcomes.

The relationship between high post-treatment hand CPT and CIPN-related DR/PD is consistent with research demonstrating that cold hyperalgesia in the upper limbs is an early marker of neurotoxicity in oxaliplatin treatment 33 . This important finding elucidates the type of impairment associated with CIPN-related DR/PD, suggesting that patients' reports to clinicians of cold pain sensitivity in the upper limbs, which may reflect hyperalgesia or allodynia in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint upper limbs, or clinician interpretation of such impairment, may play a role in CIPN-related DR/PD decision-making.

Interestingly, foot CPT was not associated with CIPN-related DR/PD. In fact, while lower limb disability, balance problems, and falls are associated with CIPN presence and severity 32, 34, 73, 74 , in this study, these factors were not associated with CIPN-related DR/PD. It is possible that sensory abnormalities in the hands have a greater impact on daily life, or are interpreted as such, than sensory abnormalities in the feet, contributing to decision-making.

Future research is needed to improve assessment and expand our understanding of lower limb impairment associated with CIPN-related DR/PD.

It is also interesting that QOL, depression, sleep and fatigue, which are associated with CIPN presence or severity 19-21 , were not associated with CIPN-related DR/PD, suggesting important variations in the factors important to each outcome. Some of this variation may be related to unknown factors guiding decision-making, which remains unclear, along with patients' understanding of decisions, their implications, and the long-term impact of CIPN. We urgently need to improve our understanding to clarify decision-making guidance due to the unclear trajectory and reversibility of CIPN.

Most intriguingly, lower pre-treatment pain catastrophizing was associated with CIPNrelated DR/PD. This may initially seem counterintuitive since higher catastrophizing is associated with greater severity of other types of cancer-related pain 75,76 . As DR/PD decisions rely on patient-clinician communication, symptom interpretation and communication models may be informative 71-73 . In particular, the Cancer Threat Interpretation Model 73 proposes that bodily sensation appraisals play a role in patient-clinician communication, especially in uncertain health contexts. Pain catastrophizing is associated with cancer-related worry 80,81 . Therefore, high . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint pre-treatment catastrophizing may reflect cancer-related worry, or a focus on worst-case possibilities in the face of survival uncertainty associated with DR/PD 82,83 , resulting in reluctance to disclose CIPN. In a qualitative study, fear of PD and resulting compromised treatment efficacy was a deterrent to CIPN disclosure 11 . Although this requires further investigation, taken together, symptom appraisal style may be critical to CIPN-related treatment decisions. Early and frequent CIPN assessment with valid and reliable tools are necessary to identify people who may underreport symptoms.

Limitations include the small sample size, preventing evaluation of DR independently from PD and the potential moderating role of dose received. Larger studies should stratify across these factors. Participants were mostly white, had few comorbidities, and were well-educated.

Moreover, those who completed both assessments were younger than those who did not complete T1. While loss-to-attrition is generally higher among older adults in similar studies 78 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263539 doi: medRxiv preprint

We thank the staff at Centre des maladies du sein Deschênes-Fabia, and Dominique St. Pierre, Marianne Vallée, and Katherine Bellavance for help with data collection, and members of the Cancer Pain and Supportive Care Research Lab for comments on earlier manuscript drafts. Most importantly, we thank the participants, whose time and efforts made this study possible. 

Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study

Fact-Taxane Functional Assessment of Cancer Therapy-Taxane, SF-MPQ-2 Short-form McGill Pain Questionnaire-2, TENS Transcutaneous Electrical Nerve Stimulation, CDT Cold detection threshold, WDT Warm detection threshold, CPT Cold pain threshold, HPT Heat pain threshold, VDT Vibration detection threshold, MDT Mechanical detection threshold, KPS Karnofsky Performance Status, TUG Timed Up and Go test, SPPB Short Physical Performance Battery protocol, FACT-G Functional assessment of cancer therapy-general

Fact-Taxane Functional Assessment of Cancer Therapy-Taxane, SF-MPQ-2 Short-form McGill Pain Questionnaire-2, TENS Transcutaneous Electrical Nerve Stimulation, QST Quantitative sensory testing, CDT Cold detection threshold, WDT Warm detection threshold, CPT Cold pain threshold, HPT Heat pain threshold, VDT Vibration detection threshold, MDT Mechanical detection threshold, KPS Karnofsky Performance Status, TUG Timed Up and Go test, SPPB Short Physical Performance Battery protocol, FACT-G Functional Assessment of Cancer Therapy-general, PSQI Pittsburgh Sleep Quality Index, FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue Scale, CES-D Center for Epidemiologic Studies-Depression scale, PCS Pain Catastrophizing Scale a Collège d'enseignement général et professionnel only in Quebec (Canada) two or three years of education after secondary school and before university, b Nab-paclitaxel and paclitaxel are collapsed, c Homogeneity of variance assumption was violated, Welch F test was used